Christopher Heeb, MD
Internal Medicine · Crestview Hills, KYNPI 1700878162
Payments from drug & device makers
Across 156 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$456
- Aimmune Therapeutics, Inc.$260
- Pfizer$257
- Lilly USA, LLC$248
- Novo Nordisk$232
- Amgen$191
- plus $967 from 29 others
What the payments were for
- Food & beverage$2,612100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $456 |
| Aimmune Therapeutics, Inc. | 2 | $260 |
| Pfizer | 17 | $257 |
| Lilly USA, LLC | 19 | $248 |
| Novo Nordisk | 14 | $232 |
| Amgen | 12 | $191 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $94 |
| GSK | 5 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $72 |
| Boehringer Ingelheim | 4 | $70 |
| Merck | 5 | $64 |
| Daiichi Sankyo Inc. | 3 | $56 |
| Xeris Pharmaceuticals, Inc. | 3 | $50 |
| Johnson & Johnson(2 entities) | 3 | $42 |
| Exact Sciences | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Novartis | 2 | $29 |
| Almatica Pharma LLC | 1 | $28 |
| Shield Therapeutics Inc | 2 | $27 |
| Bayer | 2 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Biogen | 1 | $21 |
| Abbott | 1 | $19 |
| Dynavax Technologies Corporation | 2 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Abiomed | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Boston Scientific | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZENPEP$240
How this compares
$2,612 in reported general payments places this provider in the 80th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 157 | $149,176 |
| JanuviaSitagliptin Phosphate | 73 | $80,403 |
| OzempicSemaglutide | 42 | $57,832 |
| TrulicityDulaglutide | 27 | $52,110 |
| JardianceEmpagliflozin | 39 | $48,201 |
| Repatha SureclickEvolocumab | 32 | $26,522 |
| OxycontinOxycodone Hcl | 17 | $26,077 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $16,925 |
| FarxigaDapagliflozin Propanediol | 19 | $16,312 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $13,037 |
| XareltoRivaroxaban | 11 | $10,772 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $8,185 |
| DuleraMometasone/Formoterol | 12 | $6,420 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $4,830 |
| SynthroidLevothyroxine Sodium | 63 | $4,379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $257 | $149,176157 claims |
| MerckJanuvia, Janumet Xr, Dulera | $64 | $99,86099 claims |
| Novo NordiskOzempic | $232 | $57,83242 claims |
| Lilly USA, LLCTrulicity | $248 | $52,11027 claims |
| Boehringer IngelheimJardiance | $70 | $48,20139 claims |
| GSKTrelegy Ellipta | $75 | $16,92512 claims |
| Johnson & JohnsonXarelto | $42 | $10,77211 claims |
| AbbVieSynthroid | $456 | $4,37963 claims |
| Almatica Pharma LLCSertraline Hcl | $28 | $1,453192 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Crestview Hills
- Barry WendtCrestview Hills$14K
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
- Christopher PhillipsPaducah$315K
- Cynthia Bowman-StroudPaducah$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.